{
    "nctId": "NCT04460898",
    "briefTitle": "RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.",
    "officialTitle": "Real-World Treatment Patterns and Outcomes in Postmenopausal, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Metastatic Breast Cancer Patients Treated With Palbociclib Plus an Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 195,
    "primaryOutcomeMeasure": "Number of Participants According to Year of Initial Diagnosis of Breast Cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n  1. Diagnosed with locoregional recurrent or metastatic female breast cancer.\n  2. Pathologically confirmed HR-positive/HER2-negative diagnosis.\n  3. Received treatment with palbociclib in combination with letrozole as initial endocrine-based therapy for advanced/metastatic breast cancer:\n\n     1. Initiated treatment with palbociclib at least 3 months following the provider's first use of palbociclib following its FDA approval.\n     2. At least 1 month of follow-up (at least one visit with the provider) after initiation of palbociclib.\n  4. Postmenopausal (or receiving surgical or medical treatment to induce menopause) at the time of initiation of palbociclib.\n  5. \u226518 year old at initiation of palbociclib.\n\n     Exclusion Criteria:\n* No exclusion criteria will be imposed for the selection of patients.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}